FI64287B - Foerfarande foer framstaellning av en faerg- och ph-stabil antibiotisk vattenhaltig parenteral produkt av ett farmaceutiskt godtagbart salt av en antibakteriell aminoglykosid - Google Patents
Foerfarande foer framstaellning av en faerg- och ph-stabil antibiotisk vattenhaltig parenteral produkt av ett farmaceutiskt godtagbart salt av en antibakteriell aminoglykosid Download PDFInfo
- Publication number
- FI64287B FI64287B FI790086A FI790086A FI64287B FI 64287 B FI64287 B FI 64287B FI 790086 A FI790086 A FI 790086A FI 790086 A FI790086 A FI 790086A FI 64287 B FI64287 B FI 64287B
- Authority
- FI
- Finland
- Prior art keywords
- solution
- aminoglycosides
- initial
- salt
- pharmaceutical
- Prior art date
Links
- 229940126575 aminoglycoside Drugs 0.000 title claims description 11
- 150000003839 salts Chemical class 0.000 title description 2
- 239000000203 mixture Substances 0.000 claims description 17
- 238000000034 method Methods 0.000 claims description 10
- 239000003963 antioxidant agent Substances 0.000 claims description 8
- BWRBVBFLFQKBPT-UHFFFAOYSA-N (2-nitrophenyl)methanol Chemical compound OCC1=CC=CC=C1[N+]([O-])=O BWRBVBFLFQKBPT-UHFFFAOYSA-N 0.000 claims description 7
- 230000003115 biocidal effect Effects 0.000 claims description 7
- 229960001435 sisomicin sulfate Drugs 0.000 claims description 7
- 239000003242 anti bacterial agent Substances 0.000 claims description 6
- 230000000844 anti-bacterial effect Effects 0.000 claims description 5
- 229940088710 antibiotic agent Drugs 0.000 claims description 5
- JVTNJDPXUPRGIE-UUEGJEJRSA-N (2r,3r,4r,5r)-2-[(1s,2r,3r,4s,6r)-4,6-diamino-3-[[(2s,3r)-3-amino-6-(aminomethyl)-3,4-dihydro-2h-pyran-2-yl]oxy]-2-hydroxycyclohexyl]oxy-5-methyl-4-(methylamino)oxane-3,5-diol;sulfuric acid Chemical compound OS(O)(=O)=O.O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@H](O)[C@H](O[C@@H]2[C@@H](CC=C(CN)O2)N)[C@@H](N)C[C@H]1N JVTNJDPXUPRGIE-UUEGJEJRSA-N 0.000 claims description 3
- 230000003078 antioxidant effect Effects 0.000 claims description 3
- CZPLANDPABRVHX-UHFFFAOYSA-N cascade blue Chemical compound C=1C2=CC=CC=C2C(NCC)=CC=1C(C=1C=CC(=CC=1)N(CC)CC)=C1C=CC(=[N+](CC)CC)C=C1 CZPLANDPABRVHX-UHFFFAOYSA-N 0.000 claims description 3
- 229960004832 netilmicin sulfate Drugs 0.000 claims description 3
- 238000002360 preparation method Methods 0.000 claims description 3
- 125000003132 pyranosyl group Chemical group 0.000 claims description 2
- LSNNMFCWUKXFEE-UHFFFAOYSA-N Sulfurous acid Chemical class OS(O)=O LSNNMFCWUKXFEE-UHFFFAOYSA-N 0.000 claims 3
- 239000000243 solution Substances 0.000 description 14
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 6
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 6
- 235000006708 antioxidants Nutrition 0.000 description 5
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 4
- URWAJWIAIPFPJE-UHFFFAOYSA-N Rickamicin Natural products O1CC(O)(C)C(NC)C(O)C1OC1C(O)C(OC2C(CC=C(CN)O2)N)C(N)CC1N URWAJWIAIPFPJE-UHFFFAOYSA-N 0.000 description 4
- 229930192786 Sisomicin Natural products 0.000 description 4
- 239000012153 distilled water Substances 0.000 description 4
- 229910052757 nitrogen Inorganic materials 0.000 description 4
- 229960005456 sisomicin Drugs 0.000 description 4
- URWAJWIAIPFPJE-YFMIWBNJSA-N sisomycin Chemical compound O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H](CC=C(CN)O2)N)[C@@H](N)C[C@H]1N URWAJWIAIPFPJE-YFMIWBNJSA-N 0.000 description 4
- 235000002639 sodium chloride Nutrition 0.000 description 4
- 235000010262 sodium metabisulphite Nutrition 0.000 description 4
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 3
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- 239000003109 Disodium ethylene diamine tetraacetate Substances 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 235000019301 disodium ethylene diamine tetraacetate Nutrition 0.000 description 3
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 3
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 3
- 229960002216 methylparaben Drugs 0.000 description 3
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 3
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 3
- 229960003415 propylparaben Drugs 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 3
- 235000010265 sodium sulphite Nutrition 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- ZBGPYVZLYBDXKO-HILBYHGXSA-N netilmycin Chemical compound O([C@@H]1[C@@H](N)C[C@H]([C@@H]([C@H]1O)O[C@@H]1[C@]([C@H](NC)[C@@H](O)CO1)(C)O)NCC)[C@H]1OC(CN)=CC[C@H]1N ZBGPYVZLYBDXKO-HILBYHGXSA-N 0.000 description 2
- 230000001590 oxidative effect Effects 0.000 description 2
- 229940001584 sodium metabisulfite Drugs 0.000 description 2
- 239000004296 sodium metabisulphite Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- CWERGRDVMFNCDR-UHFFFAOYSA-N thioglycolic acid Chemical compound OC(=O)CS CWERGRDVMFNCDR-UHFFFAOYSA-N 0.000 description 2
- QIJRTFXNRTXDIP-UHFFFAOYSA-N (1-carboxy-2-sulfanylethyl)azanium;chloride;hydrate Chemical compound O.Cl.SCC(N)C(O)=O QIJRTFXNRTXDIP-UHFFFAOYSA-N 0.000 description 1
- URWAJWIAIPFPJE-VHLNBGGKSA-N (2r,3r,4r,5r)-2-[(1s,2r,3r,4s,6r)-4,6-diamino-3-[[(2s,3r)-3-amino-6-(aminomethyl)-3,4-dihydro-2h-pyran-2-yl]oxy]-2-hydroxycyclohexyl]oxy-5-methyl-4-(methylamino)oxane-3,5-diol Chemical compound O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@H](O)[C@H](O[C@@H]2[C@@H](CC=C(CN)O2)N)[C@@H](N)C[C@H]1N URWAJWIAIPFPJE-VHLNBGGKSA-N 0.000 description 1
- CIKNYWFPGZCHDL-ZHFUJENKSA-N (2r,3r,4r,5r)-2-[(1s,2s,3r,4s,6r)-4,6-diamino-3-[[(2s,3r)-3-amino-6-(aminomethyl)-3,4-dihydro-2h-pyran-2-yl]oxy]-2-hydroxycyclohexyl]oxy-5-methyl-4-(methylamino)oxane-3,5-diol;sulfuric acid Chemical compound OS(O)(=O)=O.OS(O)(=O)=O.OS(O)(=O)=O.OS(O)(=O)=O.OS(O)(=O)=O.O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H](CC=C(CN)O2)N)[C@@H](N)C[C@H]1N.O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H](CC=C(CN)O2)N)[C@@H](N)C[C@H]1N CIKNYWFPGZCHDL-ZHFUJENKSA-N 0.000 description 1
- XUSXOPRDIDWMFO-CTMSJIKGSA-N (2r,3r,4r,5r)-2-[(1s,2s,3r,4s,6r)-4,6-diamino-3-[[(2s,3r)-3-amino-6-[(1s)-1-aminoethyl]-3,4-dihydro-2h-pyran-2-yl]oxy]-2-hydroxycyclohexyl]oxy-5-methyl-4-(methylamino)oxane-3,5-diol Chemical compound O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H](CC=C(O2)[C@H](C)N)N)[C@@H](N)C[C@H]1N XUSXOPRDIDWMFO-CTMSJIKGSA-N 0.000 description 1
- DYIOSHGVFJTOAR-JGWLITMVSA-N (2r,3r,4s,5r)-6-sulfanylhexane-1,2,3,4,5-pentol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)CS DYIOSHGVFJTOAR-JGWLITMVSA-N 0.000 description 1
- 241001550224 Apha Species 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- CIWBSHSKHKDKBQ-DUZGATOHSA-N D-isoascorbic acid Chemical compound OC[C@@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-DUZGATOHSA-N 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- XUSXOPRDIDWMFO-UHFFFAOYSA-N Verdamicin Natural products O1CC(O)(C)C(NC)C(O)C1OC1C(O)C(OC2C(CC=C(O2)C(C)N)N)C(N)CC1N XUSXOPRDIDWMFO-UHFFFAOYSA-N 0.000 description 1
- GKHOLUJNLGYFHA-UHFFFAOYSA-N [Na].CC(C)=O Chemical compound [Na].CC(C)=O GKHOLUJNLGYFHA-UHFFFAOYSA-N 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 238000003491 array Methods 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000013256 coordination polymer Substances 0.000 description 1
- 229960001305 cysteine hydrochloride Drugs 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 235000010350 erythorbic acid Nutrition 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 229940026239 isoascorbic acid Drugs 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- PJUIMOJAAPLTRJ-UHFFFAOYSA-N monothioglycerol Chemical compound OCC(O)CS PJUIMOJAAPLTRJ-UHFFFAOYSA-N 0.000 description 1
- 229960000808 netilmicin Drugs 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- XWGJFPHUCFXLBL-UHFFFAOYSA-M rongalite Chemical compound [Na+].OCS([O-])=O XWGJFPHUCFXLBL-UHFFFAOYSA-M 0.000 description 1
- 230000001932 seasonal effect Effects 0.000 description 1
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
- 239000004289 sodium hydrogen sulphite Substances 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 1
- 235000019345 sodium thiosulphate Nutrition 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 229940035024 thioglycerol Drugs 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 239000002351 wastewater Substances 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Inorganic Chemistry (AREA)
- Dermatology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Saccharide Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US05/869,741 US4223022A (en) | 1978-01-16 | 1978-01-16 | Stabilized aminoglycoside antibiotic formulations |
| US86974178 | 1978-01-16 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| FI790086A7 FI790086A7 (fi) | 1979-07-17 |
| FI64287B true FI64287B (fi) | 1983-07-29 |
Family
ID=25354179
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FI790086A FI64287B (fi) | 1978-01-16 | 1979-01-11 | Foerfarande foer framstaellning av en faerg- och ph-stabil antibiotisk vattenhaltig parenteral produkt av ett farmaceutiskt godtagbart salt av en antibakteriell aminoglykosid |
Country Status (24)
| Country | Link |
|---|---|
| US (1) | US4223022A (pl) |
| EP (1) | EP0003150B1 (pl) |
| JP (1) | JPS5914447B2 (pl) |
| AR (1) | AR223967A1 (pl) |
| AT (1) | AT364715B (pl) |
| AU (1) | AU524288B2 (pl) |
| BG (1) | BG32561A3 (pl) |
| CA (1) | CA1129344A (pl) |
| DD (1) | DD141410A5 (pl) |
| DE (1) | DE2961370D1 (pl) |
| DK (1) | DK155306C (pl) |
| ES (1) | ES476754A1 (pl) |
| FI (1) | FI64287B (pl) |
| GR (1) | GR73655B (pl) |
| IE (1) | IE48254B1 (pl) |
| IL (1) | IL56409A (pl) |
| MY (1) | MY8500050A (pl) |
| NO (1) | NO153876C (pl) |
| NZ (1) | NZ189363A (pl) |
| PH (1) | PH18571A (pl) |
| PL (1) | PL119296B1 (pl) |
| PT (1) | PT69063A (pl) |
| SU (1) | SU976837A3 (pl) |
| ZA (1) | ZA7962B (pl) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4327087A (en) * | 1978-01-16 | 1982-04-27 | Schering Corporation | Stabilized Netilmicin formulations |
| HU197514B (en) * | 1985-03-07 | 1989-04-28 | Chinoin Gyogyszer Es Vegyeszet | Process for production of injection sulution containing acid-additional salts od sysomicin |
| US5124317A (en) | 1985-08-02 | 1992-06-23 | Farmitalia Carlo Erba S.P.A. | Injectable ready-to-use solutions containing an antitumor anthracycline glycoside |
| US5977082A (en) * | 1985-08-02 | 1999-11-02 | Pharmacia & Upjohn Company | Injectable ready-to-use solutions containing an antitumor anthracycline glycoside |
| ATE59290T1 (de) * | 1986-03-07 | 1991-01-15 | American Cyanamid Co | Stabile injizierbare arzneiformulierung des 1,4- dihydroxy-5,8-bis((2-(hydroxyaethylamino)|thyl)amino)anthrachinondihydrochlorids. |
| JPH05236765A (ja) * | 1992-02-20 | 1993-09-10 | Okuma Mach Works Ltd | ローテータブル・リニア・アクチュエータ |
| JPH0630206U (ja) * | 1992-09-14 | 1994-04-19 | 川崎重工業株式会社 | 締固め機械の安全ガード装置 |
| US5912228A (en) * | 1995-01-13 | 1999-06-15 | Xoma Corporation | Therapeutic compositions comprising bactericidal/permeability-increasing (BPI) protein products |
| US7794713B2 (en) | 2004-04-07 | 2010-09-14 | Lpath, Inc. | Compositions and methods for the treatment and prevention of hyperproliferative diseases |
| US7862812B2 (en) | 2006-05-31 | 2011-01-04 | Lpath, Inc. | Methods for decreasing immune response and treating immune conditions |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS4911403B1 (pl) | 1970-12-29 | 1974-03-16 | ||
| US3832286A (en) * | 1971-02-03 | 1974-08-27 | Schering Corp | Sisomicin and methods for its production |
| US3995635A (en) * | 1971-09-09 | 1976-12-07 | Alza Corporation | Ocular insert |
| US3956068A (en) | 1972-07-14 | 1976-05-11 | Schering Corporation | Antibiotic G-52 and method for the production thereof |
| GB1405283A (en) | 1972-08-17 | 1975-09-10 | Scherico Ltd | Antibiotics and processes for their preparation |
| US3880828A (en) | 1973-02-23 | 1975-04-29 | Schering Corp | Antibiotics 66-40B and 66-40D from micromonospora inyoensis |
| US3898330A (en) * | 1973-08-01 | 1975-08-05 | Squibb & Sons Inc | Corticosteroid phosphate salts/neomycin sulfate ophthalmic |
| US3962429A (en) * | 1973-08-01 | 1976-06-08 | Chugai Seiyaku Kabushiki Kaisha | Method for reducing side effects of aminoglycoside antibiotics and composition therefor |
| US3944064A (en) * | 1973-10-26 | 1976-03-16 | Alza Corporation | Self-monitored device for releasing agent at functional rate |
| US4011390A (en) * | 1974-02-15 | 1977-03-08 | Schering-Plough Corporation | Semi-synthetic aminocyclitol aminoglycoside antibiotics and methods for the preparation thereof |
| US4002742A (en) * | 1974-03-19 | 1977-01-11 | Schering Corporation | 1-N-alkyl-4,6-di-(aminoglycosyl)-1,3-diaminocyclitols, methods for their manufacture, methods for their use as antibacterial agents, and compositions useful therefor |
| US4009328A (en) * | 1975-05-02 | 1977-02-22 | Schering Corporation | Aminoglycoside 66-40C, method for its manufacture, method for its use as an intermediate in the preparation of known antibiotics and novel antibacterials |
| GB1529243A (en) * | 1976-02-25 | 1978-10-18 | Pfizer Ltd | Process for the preparation of aminoglycoside derivatives and cyclic urethane intermediates for use therein |
-
1978
- 1978-01-16 US US05/869,741 patent/US4223022A/en not_active Expired - Lifetime
-
1979
- 1979-01-08 ZA ZA00790062A patent/ZA7962B/xx unknown
- 1979-01-10 EP EP79200014A patent/EP0003150B1/en not_active Expired
- 1979-01-10 DE DE7979200014T patent/DE2961370D1/de not_active Expired
- 1979-01-11 CA CA319,474A patent/CA1129344A/en not_active Expired
- 1979-01-11 GR GR58067A patent/GR73655B/el unknown
- 1979-01-11 AT AT0020479A patent/AT364715B/de not_active IP Right Cessation
- 1979-01-11 PT PT69063A patent/PT69063A/pt unknown
- 1979-01-11 ES ES476754A patent/ES476754A1/es not_active Expired
- 1979-01-11 NO NO790085A patent/NO153876C/no unknown
- 1979-01-11 IE IE45/79A patent/IE48254B1/en unknown
- 1979-01-11 NZ NZ189363A patent/NZ189363A/en unknown
- 1979-01-11 PH PH22047A patent/PH18571A/en unknown
- 1979-01-11 IL IL56409A patent/IL56409A/xx unknown
- 1979-01-11 FI FI790086A patent/FI64287B/sv not_active Application Discontinuation
- 1979-01-12 DK DK014579A patent/DK155306C/da not_active IP Right Cessation
- 1979-01-12 JP JP54002871A patent/JPS5914447B2/ja not_active Expired
- 1979-01-12 AU AU43320/79A patent/AU524288B2/en not_active Expired
- 1979-01-15 PL PL1979212809A patent/PL119296B1/pl unknown
- 1979-01-15 DD DD79210480A patent/DD141410A5/de not_active IP Right Cessation
- 1979-01-15 SU SU792709256A patent/SU976837A3/ru active
- 1979-01-16 BG BG042100A patent/BG32561A3/bg unknown
- 1979-02-11 AR AR275143A patent/AR223967A1/es active
-
1985
- 1985-12-30 MY MY50/85A patent/MY8500050A/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| DK155306B (da) | 1989-03-28 |
| PT69063A (en) | 1979-02-01 |
| CA1129344A (en) | 1982-08-10 |
| AU524288B2 (en) | 1982-09-09 |
| DK14579A (da) | 1979-07-17 |
| AT364715B (de) | 1981-11-10 |
| IL56409A0 (en) | 1979-03-12 |
| EP0003150A1 (en) | 1979-07-25 |
| FI790086A7 (fi) | 1979-07-17 |
| AR223967A1 (es) | 1981-10-15 |
| DK155306C (da) | 1989-08-28 |
| NO153876C (no) | 1989-08-22 |
| ATA20479A (de) | 1981-04-15 |
| PL212809A1 (pl) | 1980-02-11 |
| NZ189363A (en) | 1984-07-06 |
| NO153876B (no) | 1986-03-03 |
| ES476754A1 (es) | 1979-12-16 |
| AU4332079A (en) | 1979-07-26 |
| ZA7962B (en) | 1979-12-27 |
| GR73655B (pl) | 1984-03-27 |
| US4223022A (en) | 1980-09-16 |
| DE2961370D1 (en) | 1982-01-28 |
| IE48254B1 (en) | 1984-11-14 |
| MY8500050A (en) | 1985-12-31 |
| SU976837A3 (ru) | 1982-11-23 |
| JPS54100346A (en) | 1979-08-08 |
| BG32561A3 (bg) | 1982-08-16 |
| NO790085L (no) | 1979-07-17 |
| IL56409A (en) | 1981-09-13 |
| EP0003150B1 (en) | 1981-11-25 |
| JPS5914447B2 (ja) | 1984-04-04 |
| PH18571A (en) | 1985-08-12 |
| PL119296B1 (en) | 1981-12-31 |
| DD141410A5 (de) | 1980-04-30 |
| IE790045L (en) | 1979-07-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FI64287B (fi) | Foerfarande foer framstaellning av en faerg- och ph-stabil antibiotisk vattenhaltig parenteral produkt av ett farmaceutiskt godtagbart salt av en antibakteriell aminoglykosid | |
| Mandell et al. | Dipivalyl epinephrine: a new pro-drug in the treatment of glaucoma | |
| Williams et al. | Studies of crystalline vitamin B1. III. Cleavage of vitamin with sulfite | |
| EP0193287B1 (en) | Etoposide preparations | |
| DE69901177T2 (de) | Platinkomplex, dessen herstellung und dessen therapeutische verwendung | |
| US20040053888A1 (en) | Cyclodextrin-containing pharmaceutical preparation | |
| Bhuyan et al. | Comparative biological activity of nogalamycin and its analogs | |
| DE2652391C3 (de) | Daunosaminylanthracyclinone, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel | |
| Cowles | The possible role of ionization in the bacteriostatic action of the sulfonamides | |
| Buur et al. | Prodrugs of 5-fluorouracil. I. Hydrolysis kinetics and physicochemical properties of various N-acyl derivatives of 5-fluorouracil | |
| RU2219917C2 (ru) | Стабильные растворы митоксантрона | |
| CY1254A (en) | Etomidate-containing compositions | |
| Oakes et al. | Doxorubicin blocks the increase in intracellular Ca++, part of a second messenger system in N1E-115 murine neuroblastoma cells. | |
| BR112019025688A2 (pt) | derivados de aminoglicosídeos e seus usos no tratamento de distúrbios genéticos | |
| Saito et al. | Similar pharmacokinetics and differential ototoxicity after administration with cisplatin and transplatin in guinea pigs | |
| CN101772347A (zh) | 正义单链RNA包膜病毒的2-氨基-2,7-双脱氧-α-D-甘油-D-葡糖-吡喃庚糖基抑制剂 | |
| EP0432630B1 (en) | Antitumor agent | |
| Ensminger et al. | Thymidine 5′-o-pivaloate: A prodrug derivative of thymidine with potential applications in high-dose methotrexate therapy | |
| US3322627A (en) | Method of treating herpes simplex infections with 5-methylamino-2'-deoxyuridine, and compositions therefor | |
| DE3877499T2 (de) | 2,6-diamino-3-phenyl-azo-pyridin enthaltendes tier- und humanarzneimittel mit antiviraler und antitumoraler aktivitaet. | |
| Lefresne et al. | Effects of acetylcholine and atropine on the release of 14C-acetylcholine formed from U-14C-glucose in rat brain cortical and striatal prisms | |
| DE3122689C2 (de) | N-Trifluoracetyl-adriamycin-14-0-hemiglutarat und -hemiadipat und diese Verbindungen enthaltende pharmazeutische Zubereitungen | |
| PT98389B (pt) | Processo de preparacao de derivados de estreptogramina | |
| Hayashi et al. | Nucleolar alterations of myocardial cells and glomerular epithelial cells in rats after a single administration of adriamycin | |
| Semonsky et al. | Antineoplastic Effect of Compound 9777-VUFB in Animals with Experimental Tumours; Its Interaction with Some Cutostatics |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Application refused |
Owner name: ESSEX LAEAEKKEET OY |